The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
about
Checkpoint Inhibitors and Their Application in Breast CancerNon-genomic and Immune Evolution of Melanoma Acquiring MAPKi ResistanceThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyHypophysitis: Evaluation and Management.Ctla-4 gene polymorphism in +49 a/g position: a case control study on patients with oral lichen planus.Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer CellsCytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis.Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with IpilimumabImmune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus.Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis.Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?Therapeutic potential and challenges of natural killer cells in treatment of solid tumorsImmunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum.CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.Restoring microenvironmental redox and pH homeostasis inhibits neoplastic cell growth and migration: therapeutic efficacy of esomeprazole plus sulfasalazine on 3-MCA-induced sarcoma.Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases.IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.Cancer immunotherapy: A need for peripheral immunodynamic monitoring.Innate immune cells for immunotherapy of autoimmune and cancer disorders.Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy.Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab.Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.High CTLA-4 expression correlates with poor prognosis in thymoma patients.On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor AntibodiesPotential function of CTLA-4 in the tumourigenic capacity of melanoma stem cells
P2860
Q26745442-81539C5C-F9B0-41B3-AB3B-EC16697EC9BAQ27853210-E1CD6B5E-686A-4D12-959D-F10550D0874EQ28076473-0F104294-93E4-4595-93F8-D01247BD172EQ33801229-7C43149F-8DB8-4D2F-8022-3CA7BE08D79BQ34500412-C5EBD68E-98E8-4D3B-8A3C-C0A967D59E75Q35543911-743C42F7-0489-466F-861E-7F9CAF464564Q35783412-7EB32694-9140-494F-903A-3F3705E55E51Q36821143-CBFD7F4D-0115-43B7-8507-09CB1F128479Q37012537-9B1C203B-1AE5-4C70-94D7-9A114224A5BFQ37150868-1E719B71-B015-4342-9E04-FBD16FBB504EQ37295753-B3406FCF-EB21-40FD-8602-5E0F0FDC068AQ38258842-E3880B09-29C4-4DAB-BA55-B43344D65DDCQ38271877-D46D20D3-F23C-461A-AD74-C1EE1271DEF2Q38478878-D0779870-10C4-4AC9-B9C4-99D74AC56866Q38549542-ED5D2C43-F7BC-4FB6-9E33-A9279FC7C3BAQ38844694-C815C2AA-2E77-4E2E-9756-F63CB0167132Q39013880-AE9E7D72-3041-456C-B637-9FCA3ABBB277Q39748066-C9ED05E5-44AC-40F2-845F-3F2565611E99Q40226135-4F4946F3-AD29-4D23-9A9A-FC2B88F3CBC3Q40758666-A82058ED-7EC5-476C-BF75-3E966EC8A493Q42366554-AFB5FF23-BBDF-4804-AFDA-36999C2D111EQ42378748-189F1BEA-DD70-4669-AF95-979C41CDDDC2Q42683596-6E0B90B9-AFD7-48B9-9AA5-9868C39D1916Q45765887-95FEA1F0-396D-4BA9-A8A8-8B5A3E77AEB4Q47561904-427FC9FB-E0E9-4A12-8D1A-7C5190A20524Q48316500-CAD083FA-8ACA-43C4-BEB6-B8A8E890EAECQ50796572-0FE41934-0AB4-4946-BF4C-3A2377470962Q51008983-5B0BE09C-7041-4F8E-A849-B038A5CB0BEBQ51722976-FCB6704E-5D24-4DBF-86B6-85E74F7E5181Q53723979-5F4E3792-8171-4F01-8C07-EA58F54D2847Q54943060-1E43B99D-FBEF-4D98-A283-0AF1718419B5Q57492388-D8EC4FA7-A10E-4FE4-8AF5-7E94D451103BQ57788678-AC57F4B8-AC31-4055-8852-74BB851563DE
P2860
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The engagement of CTLA-4 on pr ...... toxicity and TNF-α production.
@en
The engagement of CTLA-4 on pr ...... toxicity and TNF-α production.
@nl
type
label
The engagement of CTLA-4 on pr ...... toxicity and TNF-α production.
@en
The engagement of CTLA-4 on pr ...... toxicity and TNF-α production.
@nl
prefLabel
The engagement of CTLA-4 on pr ...... toxicity and TNF-α production.
@en
The engagement of CTLA-4 on pr ...... toxicity and TNF-α production.
@nl
P2093
P2860
P50
P921
P356
P1476
The engagement of CTLA-4 on pr ...... toxicity and TNF-α production.
@en
P2093
Anna Morabito
Francesca Tosetti
Gabriella Pietra
Guido Ferlazzo
Lung-Ji Chang
Maria Cristina Mingari
Maria Pia Pistillo
Patrizia Piccioli
Sandra Salvi
Silvia Boero
P2860
P2888
P356
10.1186/1479-5876-11-108
P577
2013-05-01T00:00:00Z
P5875
P6179
1011705635